🌎 Real clinical case in my practice.
🏥 mCRPC, 177LU/PSMA post chemo.
PSA, Symptomatic, and images response after 2 cycles.

For patients who have completed 6 cycles of 177Lu-PSMA treatment and meet relevant PET criteria, the majority opinion (59%) supports re-treatment only if there was a response duration of more than 6 months.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano…

How to manage if there is no remaining uptake after 2 cycles?

For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus!

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin…

The majority, at 70%, recommend imaging for response monitoring during 177Lu-PSMA treatment in the absence of clinical progression in most patients, indicating a consensus that regular imaging is crucial for effective treatment!

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin…

I would say that logistic is an important factor to recommend Lutetium-177 or cabazitaxel for symptomatic patients in this situation

No consensus!

When evaluating patients for 177Lu-PSMA therapy eligibility, the most commonly recommended imaging is PSMA PET and FDG PET selectively for equivocal cases, as 43% of respondents chose this option. Meanwhile, 33% recommend PSMA PET and bone scintigraphy, and 24%…

For chemotherapy-fit patients with PSMA imaging-positive mCRPC who have already received one line of ARPI and one line of taxane-based chemotherapy, there is a strong consensus (96% of votes) favoring the use of 177Lu-PSMA therapy when no actionable molecular alteration is…

Actually, the consensus is docetaxel for both situation

How to utilize presence or absence of CT findings on a PSMA PET/CT
Fantastic talk by prof. Stefano Fanti
☢️ 'WITH GREAT POWER COMES GREAT RESPONSIBILITY.'
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen…

Michael Hofman Alternative PSMA ligands for diagnostics & treatment:
Are they interchangeable? Outstanding overview!
☢️ Do they have similar safety & efficacy: radioequivalent
☢️ Precision medicine: patient selections is key
☢️ Please: don't treat blindly!
☢️ Best PSMA radiotracer…

Who should receive chemotherapy before PSMA radioligand therapy?
Clinically very relevant question!
M.R.Smith

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen Emre Yekedüz Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji…

Dosing of radioligand therapy in special situations and/or toxicity! L. Emmett
⭕️ Heterogeneity predicts toxicity and response!
⭕️Less data about delayed toxicity
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast!…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 How to select mCRPC pts #ProstateCancer for lutetium-177 RLT therapy ?👉excellent talk by Thomas Hope 👉select pts based on ⬆️uptake than liver, post-Rx SPECT (+conventional scans) & not PSMA-PET should be done to follow pts👇 OncoAlert PCF Science

PSMA PET selection of patients
Thomas Hope
☢️ Baseline PSMA relates response
☢️ Patients for PSMA RLT should be selected based on uptake greater than liver!
☢️ Repeat imaging (preferably with post-treatment (SPECT) should be performed to evaluate PSMA uptake
#APCCC24 …

Ken Herrmann on “PSMA radioligand therapy - state of the art”
☢️PSMA-Lu is here and more RLT to come! Tx Monitoring an important challenge
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James…

A significant 80% of respondents report that genetic evaluation (germline and/or somatic) does influence their decision-making for the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) when testing is available without restrictions outside of a…

Prime time for PSMA at #APCCC24 !

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James Christopher Sweeney, MBBS GU Cast | Urology podcast! Joaquin Mateo LARVOL Renu Eapen Emre Yekedüz Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji Neeraj Agarwal, MD, FASCO @uromigos…

A significant majority of respondents, 76%, do not let genetic evaluation results influence their first-line treatment decisions for metastatic hormone-sensitive prostate cancer (mHSPC) outside clinical trials, provided that testing is unrestricted.

#APCCC24 Advanced Prostate Cancer Consensus Conference…

The majority of responses indicate a preference for both germline and somatic genetic testing in patients with metastatic castration-resistant prostate cancer (mCRPC), which is done regardless of somatic findings.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert…